Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Mallinckrodt_Pharmaceuticals
|
| gptkbp:acquisitionYear |
August 2014
|
| gptkbp:CEO |
Don M. Bailey
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
treatments for rare diseases
|
| gptkbp:founded |
1990
|
| gptkbp:headquartersLocation |
gptkb:Anaheim,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Questcor Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableEvent |
subject of pricing controversy regarding Acthar Gel
|
| gptkbp:notableProduct |
H.P. Acthar Gel
|
| gptkbp:numberOfEmployees |
about 390 (2013)
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
QCOR
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:bfsParent |
gptkb:Mallinckrodt_Pharmaceuticals
gptkb:Mallinckrodt |
| gptkbp:bfsLayer |
7
|